NM
FBRX icon

Newtyn Management’s Forte Biosciences FBRX Stock Holding History

Newtyn Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,430
Closed -$415K – 59
2023
Q1 		$415K Sell
16,430
-5,520
-25% -$139K 0.08% 71
2022
Q4 		$549K Buy
21,950
+1,950
+10% +$50K 0.11% 62
2022
Q3 		$535K Buy
+20,000
New +$635K 0.12% 65

Other funds holding FBRX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OWP
Old Well Partners Charlotte, North Carolina $4.55M AUM 27.75% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Newtyn Management's FBRX Position: Q2 2023 in Review

Newtyn Management sold out of Forte Biosciences (FBRX) in Q2 2023, closing a stake of 16,430 shares — an estimated $415K sold.

Newtyn Management first reported a position in FBRX in Q3 2022 and held it in 3 quarters. The position peaked at $549K in Q4 2022. 31 funds tracked by Wall St. Rank hold FBRX as of Q2 2023.

  • Newtyn Management reported no remaining Forte Biosciences position as of Q2 2023 after selling out during the quarter.
  • Newtyn Management sold 16,430 Forte Biosciences shares in Q2 2023, an estimated $415K.
  • Newtyn Management first reported a position in Forte Biosciences in Q3 2022 and held it in 3 quarters.
  • Newtyn Management's Forte Biosciences position peaked at $549K in Q4 2022.
  • 31 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2023.

Based on Newtyn Management's 13F filing for Q2 2023, filed 14 Aug 2023.